Working Together to Safely Advance Cell & Gene Therapies
September 27, 2022
Dr John Maher of King’s College London and Leucid Bio, and featuring Dr Alastair King, Dr Francisca Neethling, and Dr Andrea Bisso
Drug development is a costly and time-consuming process associated with a significant attrition rate in the clinic. Safety is an important factor in this, and is a particular issue for cell and gene therapies. A panel moderated by Dr John Maher of King’s College London and Leucid Bio, and featuring Dr Alastair King, Dr Francisca Neethling, and Dr Andrea Bisso, discuss this highly topical barrier to the further clinical and commercial success of the field.
What are the primary safety considerations at the preclinical stage?
How do we create more predictive approaches for advanced therapies?
What will be the greatest challenges to implementing non-animal alternatives in preclinical testing?
How to modify existing platforms?
How to choose an outsourcing partner, and what is the primary role of the CRO?
Do virtual companies have special needs regarding assay and safety considerations?
How can we work together to safely advance cell and gene therapies?